QualityStocksNewsBreaks – Axsome Therapeutics, Inc. (NASDAQ: AXSM) Featured in Mizuho Securities Research Report
Axsome Therapeutics (NASDAQ: AXSM) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “AXS-05 Accepted and Granted Priority Review for Major Depressive Disorder: Axsome announced today that the FDA has accepted the company's New Drug Application (‘NDA’) for AXS-05 for the major depressive disorder (‘MDD’) indication. Importantly, the FDA has also granted the application Priority Review status, which shortens the review time from ten months to six months and sets up a Prescription Drug User Fee Act (‘PDUFA’) target action date of August 22, 2021. The news is in-line with our expectations,…
